Bortezomib-based Therapy — Multiple Myeloma

Multiple myeloma is a plasma cell malignancy that is highly responsive to proteasome inhibitor-based therapy. Bortezomib (Velcade), Carfilzomib and Ixazomib are the key proteasome inhibitors used in myeloma treatment. At our centre, myeloma management follows evidence-based protocols such as VRd (Bortezomib + Lenalidomide + Dexamethasone), CyBorD (Cyclophosphamide + Bortezomib + Dexamethasone) and others based on transplant eligibility and patient fitness. Lenalidomide (an immunomodulatory drug) maintenance therapy is also offered post-transplant or in non-transplant eligible patients. Daratumumab (anti-CD38 monoclonal antibody) is incorporated in eligible patients. Regular paraprotein monitoring, bone surveys and renal function assessment guide treatment decisions.

📋 Treatment Overview

📅 Schedule a Consultation

Talk to Dr. Joshi about whether this treatment is right for you. OPD: Mon–Thu, 10 AM – 1 PM.